The American Board of Precision Medicine (ABOPM) is a pioneering medical education non-profit organization dedicated to bridging the gap between cutting-edge scientific research and the real-world clinical applications of precision medicine. Founded in 2023, ABOPM works to enhance public health outcomes by integrating multi-omics, systems biology, and advanced medical innovations into clinical practice. Our mission is to empower physicians, researchers, and institutions with the knowledge and resources needed to revolutionize patient care. Through board certification, residency training, public awareness initiatives, and policy advocacy, ABOPM is shaping the future of medicine by promoting a personalized, preventive, and data-driven approach to healthcare.

The Brazilian Society of Personalized Medicine (SBMP) is a non-profit scientific medical association that brings together highly qualified physicians, researchers, and academics dedicated to defending personalized medical practice. Founded on the principles of ethical and scientific rigor and professional autonomy, SBMP is at the forefront of discussions regarding personalized hormonal and metabolic therapies, promoting continuing medical education and the development of safety guidelines for the benefit of public health. It currently features approximately 1,000 affiliated doctors.

Journal of Clinical Medicine (ISSN: 2077-0383; Impact Factor: 3.3; CiteScore: 5.2) is an international, peer-reviewed, open access journal on clinical and pre-clinical research. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced. There is, in addition, a unique feature of this journal: it accepts studies showing meaningful but negative results. While there are many journals that focus on clinical studies, only a few of them actively accept negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already carried out.

Medicina (ISSN: 1648-9144; Impact factor: 2.9; CiteScore: 4.6), launched in 1920, is an international, open access journal advancing knowledge in the field of Human Medicine, which was established by the Lithuanian University of Health Sciences and has been published by MDPI since the beginning of 2018. The journal’s main focus is on reviews as well as clinical and experimental investigations. The journal aims to advance knowledge related to problems in medicine in developing countries as well as developed economies, to disseminate research on global health, and to promote and foster prevention and treatment of diseases worldwide. Medicina publications cater to clinicians, diagnosticians and researchers, and serve as a forum to discuss the current status of health-related matters and their impact on a global and local scale.